Trial Profile
Effectiveness of DNA Hypomethylating Agents and Lenalidomide in Elderly Patients With Myeloid Malignancies in the United States
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 15 Mar 2023
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Lenalidomide (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- 09 Mar 2023 Status changed from active, no longer recruiting to withdrawn prior to enrolment.
- 09 Apr 2019 Planned primary completion date changed from 30 Sep 2018 to 30 Sep 2020.
- 09 Apr 2019 Status changed from not yet recruiting to active, no longer recruiting.